Effects of adriamycin on chronic cardiotoxicity in selenium-deficient rats

C. Coudray,S. Mouhieddine,M. Richard,J. Arnaud,J. Leiris,A. Favier

DOI: https://doi.org/10.1007/BF00801964

IF: 12.416

1992-03-01

Basic Research in Cardiology

Abstract:

What problem does this paper attempt to address?

Evaluation of intraductal papillary mucinous neoplasms of the pancreas on MDCT and MRI]

Dali Wang,Jian Zhou,Shuangli Zheng,Jianyu Xia,Hongjie Hu

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2014.09.009

2014-01-01

Abstract:The purpose of our study was to evaluate the predictive factors of the presence of invasive carcinoma associated with intraductal papillary mucinous neoplasm (IPMN) of the pancreas on MDCT and MRI.Preoperative MDCT or/and MRI of 27 consecutive patients (19 men, 8 women, mean age 61.3 years) who had undergone surgical resection and had a pathological diagnosis of IPMN were retrospectively assessed. The type of ductal involvement, solid appearance of the lesion, location, tumor size of branch duct type and combined type lesions, maximum diameter of the tumor, caliber of the main pancreatic duct and the extent of the common bile duct dilatation were assessed on CT and MRI and correlated with the pathological findings of the invasive carcinoma. Two abdominal radiologists reviewed all the images, and when discrepancies of the findings were found, the consensus was reached by discussion.Pathological analysis revealed carcinoma in situ in two patients and invasive carcinoma in 19 patients arising from the IPMN. The type of ductal involvement (P = 0.038), a solid mass (P = 0.003) and the common bile duct dilatation ( ≥ 15 mm, P = 0.004) were correlated with the presence of associated invasive carcinoma. For the finding of solid and cystic mass in predicting invasive IPMN, the sensitivity was 66.7% (8/12) and specificity was 100.0% (8/8), and for bile duct diameter ≥ 15 mm, the sensitivity was 47.4% (9/19) and specificity was 100.0% (8/8). However, no association was found between the location of the lesion and associated invasive carcinoma. The caliber of the main pancreatic duct of patients with associated invasive carcinoma was significantly larger than that in the cases without invasive carcinoma (8.07 ± 2.23 mm vs. 4.86 ± 1.86 mm, P = 0.002). When using the main pancreatic duct dilatation ≥ 4 mm as the threshold, the sensitivity and specificity in predicting invasive IPMN were 94.7% (18/19) and 37.5% (3/8), respectively. For the branch duct type and combined type, the size of the tumor with associated invasive carcinoma was significantly larger than these without invasive carcinoma (41.35 ± 12.58) mm vs. (23.76 ± 8.06) mm (P = 0.003). When the maximum diameter was ≥ 40 mm, the sensitivity and specificity in predicting invasive IPMN were 50.0% (6/12) and 87.5% (7/8), respectively.The findings of CT and MRI are helpful to predict invasive carcinoma associated with IPMN, which may play an important role in the preoperative evaluation, surgical planning and predicting the prognosis of IPMN.
Purification of multiple heat shock proteins from a single tumor sample.

A. Ménoret,Gillian L. Bell

DOI: https://doi.org/10.1016/S0022-1759(00)00137-X

2000-04-03

Abstract:
Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas

Thomas Schnelldorfer,Michael G Sarr,David M Nagorney,Lizhi Zhang,Thomas C Smyrk,Rui Qin,Suresh T Chari,Michael B Farnell

DOI: https://doi.org/10.1001/archsurg.143.7.639

Abstract:Hypothesis: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized disease of the pancreas. We report our experience with pancreatic resection for IPMN. Design: Retrospective review from 1992 through 2005 with additional independent histopathologic confirmation. Setting: Mayo Clinic Rochester, a tertiary care center. Patients: All patients who underwent primary resection for pancreatic IPMN. Main outcome measures: Disease-specific operative outcomes, survival, and recurrence patterns. Results: Of 208 patients (mean age, 66 years) with IPMN of the pancreas, 168 underwent partial pancreatectomy, and 40 underwent total pancreatectomy; 88 were classified as having adenoma, 38 as having borderline neoplasm, 19 as having carcinoma in situ, and 63 as having invasive carcinoma. The prevalence of a malignant neoplasm was 64% in patients with main duct IPMN compared with 18% in patients with branch duct IPMN. Re-resection of the initial pancreatic margin was necessary in 21% of patients. Final negative margins were achieved in 89% of patients. Five-year survival with noninvasive IPMN was 94%. Patients with invasive IPMN had a similar 5-year survival compared with a matched cohort with ductal adenocarcinoma (31% vs 24%; P = .26). In patients with invasive IPMN, 58% experienced disease recurrence. In patients with noninvasive IPMN, 10% experienced disease recurrence after partial pancreatectomy and 0% experienced disease recurrence after total pancreatectomy. Conclusions: Patients with main duct IPMN or high-risk branch duct IPMN should be considered for targeted pancreatectomy. Invasive IPMN behaves as aggressively as ductal adenocarcinoma, but resection seems to provide the only potential for cure. Even with negative resection margins, the pancreatic remnant harbors a risk of recurrence and, thus, careful long-term surveillance is warranted.
Phylogenetic Relationships of Pseudorasbora, Pseudopungtungia, and Pungtungia (Teleostei; Cypriniformes; Gobioninae) Inferred from Multiple Nuclear Gene Sequences

Keun-Yong Kim,M. Ko,Huanzhang Liu,Q. Tang,Xiang-lin Chen,J. Miyazaki,I. Bang

DOI: https://doi.org/10.1155/2013/347242

2013-09-10

BioMed Research International

Abstract:Gobionine species belonging to the genera Pseudorasbora, Pseudopungtungia, and Pungtungia (Teleostei; Cypriniformes; Cyprinidae) have been heavily studied because of problems on taxonomy, threats of extinction, invasion, and human health. Nucleotide sequences of three nuclear genes, that is, recombination activating protein gene 1 (rag1), recombination activating gene 2 (rag2), and early growth response 1 gene (egr1), from Pseudorasbora, Pseudopungtungia, and Pungtungia species residing in China, Japan, and Korea, were analyzed to elucidate their intergeneric and interspecific phylogenetic relationships. In the phylogenetic tree inferred from their multiple gene sequences, Pseudorasbora, Pseudopungtungia and Pungtungia species ramified into three phylogenetically distinct clades; the “tenuicorpa” clade composed of Pseudopungtungia tenuicorpa, the “parva” clade composed of all Pseudorasbora species/subspecies, and the “herzi” clade composed of Pseudopungtungia nigra, and Pungtungia herzi. The genus Pseudorasbora was recovered as monophyletic, while the genus Pseudopungtungia was recovered as polyphyletic. Our phylogenetic result implies the unstable taxonomic status of the genus Pseudopungtungia.
Epithelial ovarian cancer and infertility treatment

A. Maclean

DOI: https://doi.org/10.1080/01443610120101600

2002-01-01

Journal of Obstetrics and Gynaecology Research

Abstract:The last issue of the Journal of Obstetrics and Gynaecology included a case report from Yasmin and colleagues: ‘Early-onset epithelial ovarian cancer in a patient who had undergone oocyte donation’. There is an increasing literature linking ovarian cancer with infertility and infertility treatment, but the case described has some important differences—she was multiparous, had no past history of infertility (and as far as is known had not been exposed to clomiphene), had only two cycles of ovarian hyperstimulation for oocyte retrieval and donation, and the histology was of a serous adenocarcinoma. Some of the details are not available because HEFA regulations make them confidential, but we may presume that her ovaries were ultrasonically normal at that time. These points are made by the authors in their discussion. The case report adds some credence to the plight of Liz Tilberis, the former editor of Vogue, who believed that her fertility treatment caused her to develop ovarian cancer. Bamford and Steele (1982) reported from the Middlesex Hospital, London, the history of a 32-yearold nulliparous woman who had undergone eight cycles of ovulation induction with gonadotrophins, followed by a 2-year gap and a further three cycles. A 4-cm ovarian cyst was noted at the time, which increased to 25 cm diameter within a month. Emergency laparotomy was performed and an ovarian endometrioid adenocarcinoma was found, along with atypical endometrial hyperplasia and adenocarcinoma. Goldberg and Runowicz (1992) reported three cases of ovarian low malignant potential tumours following ovulation induction; all three were serous in histological type. Each of the patients had received two or three cycles of Pergonal for gonadotrophin induction of ovulation or for in vitro fertilisation. Land (1993) reviewed the literature up to that time and reported on ten cases of ovarian neoplasia developing during or soon after ovulation induction therapy. The patients were young, ranging between 22 and 38 years, and seven of the 10 were borderline or low malignant potential tumours. Apart from the case reported by Bamford and Steele, the histology on the other nine was serous or serous papillary type. Rossing et al. (1994) reviewed a cohort of 3837 women from Seattle who had been evaluated for infertility between 1974 and 1985. Eleven were subsequently found to have ovarian tumours but two were granulosa cell tumours, five were borderline tumours, and only four were epithelial ovarian cancers. The authors demonstrated an increased risk with clomiphene use, particularly if more than 12 cycles were used. The five borderline tumours were two serous papillary, two mucinous and one mucinous papillary histological type, while the four invasive tumours were two mucinous, one endometrioid and one adenocarcinoma without further classification. It should be noted that the Committee on Safety of Medicines now recommends, on the basis of Rossing’s data, that clomiphene should not normally be used for more than six cycles. Other cases continue to be reported (e.g. Hull et al., 1996; Unkila-Kallio et al., 1997) and the majority are of serous papillary type, although malignant teratoma, granulosa cell tumour and mucinous adenocarcinoma are included. However, the argument is not all one way, and several large studies have reported negative associations. Franceschi et al. (1994) analysed the relationship between fertility drugs and ovarian cancer in a case– control study (195 epithelial ovarian cancer cases and 1339 control cases) in four areas in Italy—they could not establish a role for ovarian stimulation from their data. Venn et al. (1995) reviewed 5564 women who had in vitro fertilisation with ovarian stimulation, and 4794 ‘unexposed’ women, i.e. had IVF without ovarian stimulation or were not treated, and in a subsequent report (Venn et al., 1999) included 29 700 women, 20 656 exposed and 9044 unexposed to fertility drugs (in 10 Australian IVF clinics). On review, the incidence of ovarian cancer was not greater than expected (by standardised incidence ratios) and no difference between exposed and unexposed women. Mosgaard et al. (1997) summarised the current position:
Alfentanil partition coefficient.

D. Stone,C. Difazio

DOI: https://doi.org/10.1213/00000539-198912000-00030

1989-12-01

Abstract:
Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers

Thaer S. A. Abdalla,Jannis Duhn,Monika Klinkhammer-Schalke,Sylke Ruth Zeissig,Kees Kleihues-van Tol,Kim C. Honselmann,Rüdiger Braun,Markus Kist,Louisa Bolm,Lennart von Fritsch,Hryhoriy Lapshyn,Stanislav Litkevych,Richard Hummel,Sergii Zemskov,Ulrich Friedrich Wellner,Tobias Keck,Steffen Deichmann

DOI: https://doi.org/10.3390/cancers16112016

2024-05-27

Cancers

Abstract:Background: Intraductal papillary mucinous neoplasms (IPMNs) are premalignant cystic neoplasms of the pancreas (CNPs), which can progress to invasive IPMN and pancreatic cancer. The available literature has shown controversial results regarding prognosis and clinical outcomes after the resection of invasive IPMN. Aims: This study aims to characterize the oncologic outcomes and metastatic progression pattern after the resection of non-metastatic invasive IPMN. Methods: Data were obtained from 24 clinical cancer registries participating in the German Cancer Registry Group of the Society of German Tumor Centers (ADT). Patients with invasive IPMN (n = 217) as well as PDAC (n = 5794) between 2000 and 2021 were included and compared regarding oncological outcomes. Results: Invasive IPMN was significantly smaller in size (p < 0.001) and of a lower tumor grade (p < 0.001), with fewer lymph node metastases (p < 0.001), lymphangiosis (p < 0.001), and consequently a higher R0 resection rate (88 vs. 74%) compared to PDAC. Moreover, invasive IPMN was associated with fewer local (11 vs. 15%) and distant recurrences (29 vs. 46%) and metastasized more frequently in the lungs only (26% vs. 14%). Invasive IPMN was associated with a longer median OS (29 vs. 19 months) and DFS (31 vs. 15 months) compared to PDAC and stayed independently prognostic in multivariable analyses. These survival differences were most pronounced in early tumor stages. Interestingly, postoperative chemotherapy was not associated with improved overall survival in surgically resected invasive IPMN. Conclusions: Invasive IPMN is a rare pancreatic entity with increasing incidence in Germany. It is associated with favorable histopathological features at the time of resection and longer OS and DFS compared to PDAC, particularly before the locoregional spread has occurred. Invasive IPMNs are associated with lung-only metastasis. The benefit of postoperative chemotherapy after the resection of invasive IPMN remains uncertain.

oncology
Elevated Percentage of L-Selectin on Peripheral Blood Τ Lymphocytes (PBTLs) in Children and Adolescents with Type 1 Diabetes Mellitus and Vascular Complications

P. Pawłowski,M. Urban,A. Stasiak-Barmuta,A. Bossowski

DOI: https://doi.org/10.1515/JPEM.2005.18.12.1449

Abstract:L-Selectin and VLA-4, playing two distinct but complimentary roles in the T-cell trafficking into the site of inflammation, are thought to have a role in the process of diabetic vascular complications". Recently, a relationship between sL-selectin level and the development of diabetic retinopathy (DR) has been described in patients with diabetes mellitus (DM). MacKinnon et al. found altered Lselectin expression in lymphocytes and increased adhesion to the endothelium in patients with DR, and suggest a role of lymphocyte activation in the pathogenesis of DR. Moreover, the serum level of VLA-4 ligand, VCAM-1, was found elevated in patients with diabetic vascular complications. L-Selectin as well as other selectins were suggested to be a surrogate marker for CAD and atherosclerosis in type 2 DM. The aim of our study was to elucidate whether there is any relationship between the percentage of L-selectin and VLA-4 Τ lymphocytes and the development of diabetic vascular complications. Our study was carried out in a group of 60 children with type 1 DM (DM1). Group 1 (n = 20) had DM1 >5 years with microvascular complications (DR, incipient nephropathy/microalbuminuria) and with arterial hypertension with medium metabolic control (median actual HbAu 8%); Group 2 (n = 20) had DM1 >5 years, without complications (with median actual HbAu 8.2%); Group 3 (n = 20) had DM1 <5 years (median actual H b A u 7.9%). All patients were under intensive insulin therapy, without ketoacidosis. Twenty healthy volunteers were matched as controls. We found that the percentage of PBTLs expressing L-selectin was elevated in patients with DM1 versus controls, and was highest in children with diabetic vascular complications, whereas the percentage of VLA-4 PBTLs was no longer decreased in this group versus healthy controls (Table 1). Furthermore, a higher proportion of Lselectin cells was observed in children with arterial hypertension than without (p <0.05). In contrast, the reduced L-selectin expression on Τ lymphocytes in patients with DM and DR versus controls found by MacKinnon et al. could be due to the smaller and more heterogeneous group of patients (with type 1 and type 2 DM). According to Kretowski et al., the baseline elevation of Lselectin level is likely to be genetically determined
The pathological features and prognoses of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm after surgical resection: a single institution series

Yuqiong Li,Zhongfei Zhu,Lisi Peng,Zhendong Jin,Liqi Sun,Bin Song

DOI: https://doi.org/10.1186/s12957-020-02063-8

2020-11-04

Abstract:Background: Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) represent the tumors with malignant transformation potential. The objective of the study was to verify their pathological characteristics, prognoses, and recurrence factors. Methods: Two hundred eighteen IPMNs and 27 MCNs resected at a single institution were included. The demographic, preoperative, histopathological, and follow-up data of the patients were recorded and analyzed. Overall survival (OS) and disease-free survival (DFS) were defined as the interval from the date of initial surgery to death or the last follow-up (OS) and to diagnosis of recurrence or death at follow-up (DFS). Results: Of the 218 IPMN and 27 MCN patients, 93 (42.7%) and 8 (29.6%) cases were malignant, respectively. IPMNs occurred in older patients compared with MCN patients (median 63 years vs 54 years, P < 0.0001), and MCNs occurred exclusively in females (100%). Of the overall study cohort, the pathological specimens presented peripheral invasion in 37 (15.1%) patients and incisal margin invasion was observed in 46 (18.8%) patients. After a median follow-up of 34 months, 37 (14.9%) patients relapsed. The 5-year OS and DFS rates of IPMNs were 97.5% and 80.6%; and the OS and DFS rates of MCNs were 95.7% and 87.0%, respectively. There were four independent risk factors associated with recurrence: pathological diagnoses with malignancy (odds ratio, OR = 3.65), presence of oncocytic type for IPMN (OR = 1.69), peripheral invasion (OR = 12.87), and incisal margin invasion (OR = 1.99). Conclusions: IPMNs and MCNs are indolent tumors with favorable prognoses after surgical resection in terms of their relatively high OS and DFS rate. Patients with malignant pathological-related diagnoses should accept strict tumor surveillance in view of their higher risk of recurrence.
Reoperation for Heterochronic Intraductal Papillary Mucinous Neoplasm of the Pancreas after Bile Duct Neoplasm Resection: A Case Report.

Gang Xiao,Tao Xia,Yi-Ping Mou,Yu-Cheng Zhou

DOI: https://doi.org/10.4240/wjgs.v15.i7.1542

2023-01-01

World Journal of Gastrointestinal Surgery

Abstract:BACKGROUND:Intraductal papillary neoplasm of the bile duct (IPNB) and intraductal papillary mucinous neoplasm (IPMN) of the pancreas have similar pathological manifestations. However, they often develop separately and it is rare for both to occur together. Patients presenting with heterochronic IPMN after IPNB are prone to be misdiagnosed with tumor recurrence.CASE SUMMARY:A 67-year-old male patient was admitted 8.5 years after IPNB carcinoma and 4 years after the discovery of a pancreatic tumor. A left hepatic bile duct tumor with distal bile duct dilatation was found 8.5 years ago by the computed tomography; therefore, a left hepatectomy was performed. The postoperative pathological diagnosis was malignant IPNB with negative cutting edge and pathological stage T1N0M0. Magnetic resonance imaging 4 years ago showed cystic lesions in the pancreatic head with pancreatic duct dilatation, and carcinoembryonic antigen continued to increase. Positron emission tomography showed a maximum standard uptake value of 11.8 in the soft tissue mass in the pancreatic head, and a malignant tumor was considered. Radical pancreatoduodenectomy was performed. Postoperative pathological diagnosis was pancreatic head IPMN with negative cutting edge, pancreaticobiliary type, stage T3N0M0. He was discharged 15 d after the operation. Follow-up for 6 mo showed no tumor recurrence, and quality of life was good.CONCLUSION:IPNB and IPMN are precancerous lesions with similar pathological characteristics and require active surgery and long-term follow-up.
Risk of Recurrence After Surgical Resection for Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasia (IPMN) With Patterns of Distribution and Treatment: An International, Multicenter, Observational Study (ADENO-IPMN Study)

J. Lucocq,S. Pandanaboyana

DOI: https://doi.org/10.1016/j.hpb.2024.03.602

IF: 13.787

2024-06-08

Annals of Surgery

Abstract:Objective: This international multicenter cohort study aims to identify recurrence patterns and treatment of first and second recurrence in a large cohort of patients after pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasm (IPMN). Background: Recurrence patterns and treatment of recurrence postresection of adenocarcinoma arising from IPMN are poorly explored. Methods: Patients undergoing pancreatic resection for adenocarcinoma from IPMN between January 2010 and December 2020 at 18 pancreatic centers were identified. Survival analysis was performed using the Kaplan-Meier log-rank test and multivariable logistic regression by Cox-Proportional Hazards modeling. End points were recurrence (time-to, location, and pattern of recurrence) and survival (overall survival and adjusted for treatment provided). Results: Four hundred fifty-nine patients were included (median, 70 years; interquartile range, 64–76; male, 54%) with a median follow-up of 78.1 months. Recurrence occurred in 209 patients [45.5%; median time to recurrence, 12.8 months; early recurrence (within 1 years), 23.2%]. Eighty-three (18.1%) patients experienced a local regional recurrence, and 164 (35.7%) patients experienced a distant recurrence. Adjuvant chemotherapy was not associated with reduction in recurrence (hazard ratio 1.09; P=0.669) One hundred twenty patients with recurrence received further treatment. The median survival with and without additional treatment was 27.0 and 14.6 months (P<0.001), with no significant difference between treatment modalities. There was no significant difference in survival between locations of recurrence (P=0.401). Conclusions: Recurrence after pancreatic resection for adenocarcinoma arising from IPMN is frequent with a quarter of patients recurring within 12 months. Treatment of recurrence is associated with improved overall survival and should be considered.

surgery
Qualitative evaluation of Project P.A.T.H.S. in Hong Kong: focus groups based on Secondary 3 program implementers

D. Shek

DOI: https://doi.org/10.1515/ijamh.2012.035

2012-01-18

International Journal of Adolescent Medicine and Health

Abstract:Abstract Ten focus groups comprising 42 program implementers recruited from 10 schools were conducted to evaluate the Tier 1 Program (Secondary 3) of Project P.A.T.H.S. (Positive Adolescent Training through Holistic Social Programs) in the 2008/09 school year. Results showed that a majority of the program implementers used positive descriptors and metaphors to represent the program and they perceived that the program benefited the program participants in various psychosocial domains. In conjunction with the previous research findings, the present study provides further support for the effectiveness of the Tier 1 Program of Project P.A.T.H.S.
Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society

Seiko Hirono,Yasuhiro Shimizu,Takao Ohtsuka,Toshifumi Kin,Kazuo Hara,Atsushi Kanno,Shinsuke Koshita,Keiji Hanada,Masayuki Kitano,Hiroyuki Inoue,Takao Itoi,Toshiharu Ueki,Toshio Shimokawa,Susumu Hijioka,Akio Yanagisawa,Masafumi Nakamura,Kazuichi Okazaki,Hiroki Yamaue

DOI: https://doi.org/10.1007/s00535-019-01617-2

2019-08-28

Journal of Gastroenterology

Abstract:<h3 class="Heading">Background</h3><p class="Para">Although there are numerous reports focusing on surgical indication for intraductal papillary mucinous neoplasm (IPMN), the recurrence patterns following surgery are less widely reported. To ascertain optimal treatment and postoperative surveillance for IPMN patients, we analyzed patterns and risk factors for recurrence after surgery for IPMN.</p><h3 class="Heading">Methods</h3><p class="Para">This study is a retrospective, multi-institutional, observational study, including 1074 patients undergoing surgery for IPMN at 11 academic institutions. We analyzed the risk factors for recurrence after classifying postoperative recurrences into metachronous high-risk lesions (malignant progression of IPMN and/or metachronous pancreatic ductal adenocarcinoma) in the remnant pancreas and extra-pancreatic recurrence.</p><h3 class="Heading">Results</h3><p class="Para">Of 1074 patients undergoing surgery for IPMN, 155 patients (14.4%) developed postoperative recurrence. We found that 34.3% of 70 high-risk lesions in the remnant pancreas occurred over 5 years after surgery, and survival of 36 patients undergoing second operation for high-risk lesions was better than that of 34 patients who did not (<em class="EmphasisTypeItalic">P</em> = 0.04). We found four independent risk factors for metachronous high-risk lesions in remnant pancreas: symptoms [<em class="EmphasisTypeItalic">P</em> = 0.005, hazard ratio (HR) 1.988], location of pancreatic body/tail (<em class="EmphasisTypeItalic">P</em> < 0.001, HR 3.876), main duct size ≥ 10 mm (<em class="EmphasisTypeItalic">P</em> = 0.021, HR 1.900), and high-grade dysplasia/invasive intraductal papillary mucinous carcinoma (IPMC) (<em class="EmphasisTypeItalic">P</em> < 0.001, HR 3.204). Although six patients (0.7%) with low- or high-grade dysplasia IPMN developed extra-pancreatic recurrence, invasive IPMC was the strongest risk factor for extra-pancreatic recurrence (<em class="EmphasisTypeItalic">P</em> < 0.001, HR 39.667).</p><h3 class="Heading">Conclusion</h3><p class="Para">We suggest that life-time continuous surveillance might be necessary for IPMN patients. Second surgery for metachronous high-risk lesions in remnant pancreas should be considered to improve survival.</p>

gastroenterology & hepatology
Inter- and intraexaminer reliability of a single, digital inclinometric range of motion measurement technique in the assessment of lumbar range of motion.

D. Stude,C. Goertz,M. Gallinger

IF: 1.3

1994-02-01

Journal of Manipulative and Physiological Therapeutics

Abstract:OBJECTIVE The between and within examiner reliability of a range of motion digital inclinometer was evaluated for lumbar flexion, extension and right and left lateral flexion. DESIGN Blinded, lumbar range of motion instrumentation reliability. SETTING Private college research and ambulatory patient care facility. PARTICIPANTS Twenty-eight asymptomatic persons recruited from a private college. This included students, staff and faculty that ranged from 23-36 yr, with no history of back pain or surgery or back injury 6 wk prior to entry into the study. INTERVENTION Lumbar range of motion examination, twice by each examiner, or four times in all per subject. MAIN OUTCOME MEASURE Lumbar range of motion, measured in degrees. RESULTS Intraclass correlation (ICC) revealed lack of reliability for this device except flexion, but intrinsic limitations of the instrument suggests that flexion as well may not be reliable. The p value of .05 was used for statistical significance and Burdock's recommended value of .75 represented the minimum R value for reliability. CONCLUSION Most of the reliability values did not meet Burdock's recommended minimum R value, and the R values for flexion may have met minimum criteria due to intrinsic limitations of the instrument itself. Due to the findings of this study, we conclude that the Orthoranger II digital inclinometer is not reliable, between and/or within examiners, for measuring lumbar flexion, extension or lateral flexion. Because there was evidence to suggest other variables which were not accounted for, and which could have affected final results, the development of a streamlined protocol may result in more consistent findings. Further research is needed to either support or dispute these results before this instrument can be recommended as an assessment tool in clinical practice or in clinical trials.
Individualized Surgical Treatment and Prognosis of Intraductal Papillary Mucinous Neoplasms of the Pancreas

Xiao-dong Tian,Guang-dong Wu,Yan Zhuang,Xiao-chao Guo,Yin-mo Yang

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2013.07.003

2013-01-01

Abstract:OBJECTIVE:To investigate the clinical manifestation, individualized surgical treatment, and prognosis of intraductal papillary mucinous neoplasms (IPMN) of pancreas.METHODS:The clinical data of 56 IPMN cases treated between January 2007 and December 2011 was retrospectively analyzed. Among the 56 patients (38 male and 18 female, mean age (61 ± 7) years), 26 were main-duct type, 18 were branch-duct type, 12 were mixed type. Pancreatectomy was performed on 48 cases, including pancreaticoduodenectomy on 29 patients, distal pancreatectomy on 17 patients, and total pancreatectomy on 2 patients.RESULTS:The overall postoperative morbidity rate was 27.1% (13/48), there was no perioperative mortality. Pathology showed 31 cases of noninvasive IPMN, 17 cases of invasive IPMN, and 7 cases of lymph node metastasis. The rate of invasive tumors was 46.2% (12/26) in main duct type, 3/12 in mixed type, and 2/18 in branch duct type IPMN, the difference was statistically significant (χ(2) = 6.385, P = 0.041). The five-year survival rate for patients with noninvasive and invasive neoplasms was 100% and 24.6%, respectively. The prognosis of invasive cases with lymph node metastasis was significantly worse than those without lymph node metastasis (P = 0.017). A regular follow-up without surgical treatment was performed on 8 cases with asymptomatic side branch IPMN less than 3 cm in diameter, and no progression was found during the follow-up.CONCLUSIONS:IPMN has a relative good prognosis. Main duct type and mixed type IPMN have a higher malignant potential, and should receive a surgical treatment. Patients of branch duct type IPMN with a <3 cm diameter lesion and no clinical manifestations can be managed with close follow-up only.
[Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002)].

I. Krakowski,S. Théobald,L. Balp,M. Bonnefoi,G. Chvetzoff,O. Collard,E. Collin,M. Couturier,T. Delorme,R. Duclos,A. Eschalier,Bernard Ffergane,F. Larue,M. Magnet,C. Minello

IF: 1.318

Bulletin du Cancer

Abstract:CONTEXT The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of french cancer centers (FNCLCC), the 20 French cancer centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. OBJECTIVES To develop clinical practice guidelines for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer according to the definitions of the Standards, Options and Recommendations project. METHODS In 1996, a working group, set up by the FNCLCC published clinical practice guidelines for pain management in adult and paediatric patients with cancer. In the light of the evolution of our knowledge, and practice these guidelines need to be updated. The section on "medical analgesic treatments" in the document published in 1996 was examined by the working group to identify which questions should be updated. These questions and the relevant key words were used to develop a search strategy which was used to search Medline , and for particular questions, Embase , from January 1994 to March 1999, for relevant references, published in English or French. RESULTS For this update, only a few randomised clinical trials were identified, and their conclusions were generally weak. Thus much of the information in this document is based on the World Health Organisation (WHO) guidelines and represents the "state of the art" on this subject in France and is supported by expert agreement. Some changes to the original SOR are presented, eg. methods of titration, prescription of new opioids, opioid rotation. We also present a synthesis of recent pharmacological and regulatory data. The integral version is available on the FNCLCC web site (http://www.fnclcc.fr/sor.htm).
An Analysis of Clinico-Pathologic Features of Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Lou Wenhui,Jin Dayong,Wang Dansong,Xu Xuefeng,Kuang Tiantao,Qin Xinyu

DOI: https://doi.org/10.1007/s11684-007-0032-4

2007-01-01

Frontiers of Medicine in China

Abstract:The natural history and clinical manifestation of resected intraductal papillary mucinous neoplasm (IPMN) of the pancreas were elucidated, and based on this, a retrospective pancreatic database was reviewed to identify patients with IPMN who were surgically managed in our department from 1999 to June 2006. Pathologic rereview of each case was performed, and the clinico-pathologic features were examined. Student's T test and χ(2) analysis were used to identify factors associated with malignancy. Fifty-one patients were identified. There were 33 males and 18 females. One patient's pancreas was unresectable, two patients underwent a total pancreatectomy, 42 patients had a pancreatecoduodenectomy and five patients had distal pancreatectomy. Main-duct type carcinoma was identified in 24 patients; branch-duct type in 15 patients, and mixed type in 12 patients. Invasive carcinoma was present in 35 patients. Weight loss and jaundice occurred more commonly in the invasive group. The average serum CA19-9 level was significantly higher in the invasive group (1542μ vs 94.5μ). The average diameter of the pancreatic duct was also wider in the invasive group (8.7 mm vs 4.3 mm). Significant predictors of malignant IPMNs included weight loss, jaundice, a high level of serum CA19-9, a large pancreatic duct and main-duct type carcinoma.
Criteria for choice and use of contrast media in intra-arterial D.S.A.

L. Dalla-Palma,F. Stacul,R. Pozzi-mucelli

IF: 4.531

1985-02-01

European Journal of Radiology

Abstract:The authors investigated the optimal characteristics of contrast media for use in intra-arterial DSA. 209 injections in 108 patients were evaluated, most of them in the abdominal and peripheral regions. In order to decrease contrast media osmolarity and obtain an adequate mixing with blood, contrast media with low iodine concentration were injected using the same volumes and flow rates of conventional arteriography. Good results were obtained with ionic contrast media, 100 and 150 mgI/ml. depending on the area investigated. The low concentrations allowed the use of ionic agents with an osmolarity very close to that of the non ionic contrast media: the pain has been eliminated and the heat sensation reduced. Furthermore the comparison with the cost of nonionic agents shows a great saving.
Data analysis of 36 cases with intraductal papillary mucinous neoplasm of the pancreas for their clinicopathological features, diagnosis, and treatment.

Chunhui Yuan,Dianrong Xiu,Ming Tao,Zhaolai Ma,Bin Jiang,Zhifei Li,Lei Li,Liang Wang,Hangyan Wang,Tonglin Zhang

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20142024

IF: 6.133

2014-01-01

Chinese Medical Journal

Abstract:Background Intraductal papillary mucinous neoplasm (IPMN) is a rare pancreatic cystic neoplasm, accounting for 1% of all exocrine pancreatic neoplasms. This study aimed to summarize the clinicopathological and biological behaviors, as well as the experience in diagnosis and treatment of IPMN. Methods Clinicopathological data were collected from 36 cases with IPMN who were treated in Department of General Surgery, Peking University Third Hospital from May 2001 to July 2011. Results The 36 cases of IPMN patients included 27 males and 9 females (M:F=3:1). The age of patients ranged from 52 to 78 years, with an average of 67.3 years. Regarding tumor location, 20 tumors were located in pancreatic head, 3 in pancreatic neck, 10 in pancreatic body and tail, and 3 in the whole pancreas. All the 36 cases underwent surgical treatment, with 13 cases of pancreaticoduodenectomy, 3 cases of middle pancreatectomy, 7 cases of tumor resection plus pancreaticojejunostomy, 3 cases of distal pancreatectomy, 7 cases of distal pancreatectomy plus spleen resection, and 3 cases of total pancreaticoduodenectomy. Of the 36 patients, 9 patients underwent the operations under laparoscopy. The 36 cases included main duct type (14 cases, 38.9%), branch duct type (10 cases, 27.7%), and mixed duct type (12 cases, 33.3%). Pathologically, of the 36 cases, there were 7 IPMN adenomas, 11 borderline IPMNs, 6 IPMN with carcinomas in situ, and 12 IPMNs with invasive carcinomas. All the 36 cases were followed up. During an average of 42 months follow-up period (26-129 months), no recurrence occurred. Conclusions IPMN, which primarily occurs in male, is a low-grade malignancy which may involve any part of the pancreas, with specific clinicopathological features. IPMN is a different malignancy type from pancreatic ductal carcinoma. Imaging and laboratory examination are helpful for the diagnosis and differential diagnosis. The prediction of invasive IPMN is still difficult. Surgical resection is recommended as the first choice of treatment. Aggressive and proper operation procedure produces better prognosis. Long-term follow-up is necessary for patients after operation. Laparoscopic distal pancreatectomy is a feasible and safe procedure for the indicated patients.
Epidemiologic Survey of Epilepsy Among Army Draftees in Lombardy, Italy

C. Cornaggia,M. Canevini,W. Christe,D. Giuccioli,M. A. Facheris,M. Sabbadini,R. Canger

DOI: https://doi.org/10.1111/j.1528-1157.1990.tb05355.x

IF: 6.74

1990-02-01

Epilepsia

Abstract:Summary: We conducted an epidemiological survey of epilepsy among males born in 1967 who were called for selection for military service from the Lombardy region in northern Italy. Of 54,520 subjects, 258 had active epilepsy (prevalence, 0.47%). Idiopathic partial epilepsy was most common (29.1%), and generalized idiopathic and/or symptomatic epilepsy was least common (3.8%). In the year preceding the interview, 66.9% of the subjects had been free of generalized tonic‐clonic seizures, 57.6% had been free of minor seizures, and 36.9% were seizure‐free. Case histories revealed a background of febrile convulsions in 18.9% of subjects, status epilepticus in 11.3%, and a family history of epilepsy in 18.9%. Physical and mental development was normal in 75.5% of the subjects. Education level of subjects was lower than a control group, and the unemployment rate was the same as the local rate.

Effects of adriamycin on chronic cardiotoxicity in selenium-deficient rats

Evaluation of intraductal papillary mucinous neoplasms of the pancreas on MDCT and MRI]

Purification of multiple heat shock proteins from a single tumor sample.

Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas

Phylogenetic Relationships of Pseudorasbora, Pseudopungtungia, and Pungtungia (Teleostei; Cypriniformes; Gobioninae) Inferred from Multiple Nuclear Gene Sequences

Epithelial ovarian cancer and infertility treatment

Alfentanil partition coefficient.

Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers

Elevated Percentage of L-Selectin on Peripheral Blood Τ Lymphocytes (PBTLs) in Children and Adolescents with Type 1 Diabetes Mellitus and Vascular Complications

The pathological features and prognoses of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm after surgical resection: a single institution series

Reoperation for Heterochronic Intraductal Papillary Mucinous Neoplasm of the Pancreas after Bile Duct Neoplasm Resection: A Case Report.

Risk of Recurrence After Surgical Resection for Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasia (IPMN) With Patterns of Distribution and Treatment: An International, Multicenter, Observational Study (ADENO-IPMN Study)

Qualitative evaluation of Project P.A.T.H.S. in Hong Kong: focus groups based on Secondary 3 program implementers

Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society

Inter- and intraexaminer reliability of a single, digital inclinometric range of motion measurement technique in the assessment of lumbar range of motion.

Individualized Surgical Treatment and Prognosis of Intraductal Papillary Mucinous Neoplasms of the Pancreas

[Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002)].

An Analysis of Clinico-Pathologic Features of Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Criteria for choice and use of contrast media in intra-arterial D.S.A.

Data analysis of 36 cases with intraductal papillary mucinous neoplasm of the pancreas for their clinicopathological features, diagnosis, and treatment.

Epidemiologic Survey of Epilepsy Among Army Draftees in Lombardy, Italy